Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6010759 | 1.00 | KCNH2 (0.41) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010669 | 0.87 | KCNH2 (0.46) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010597 | 0.87 | KCNH2 (0.46) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL5542294 | 0.87 | KCNH2 (0.44) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL5542301 | 0.87 | KCNH2 (0.44) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010604 | 0.87 | KCNH2 (0.46) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010854 | 0.84 | KCNH2 (0.41) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010858 | 0.84 | KCNH2 (0.41) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010742 | 0.81 | KCNH2 (0.46) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C | |
| SCHEMBL6010737 | 0.78 | KCNH2 (0.42) | KCNH2PTGS1SLC6A2SLC6A4CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KCNH2 3503/4885PTGS1 3838/4885SLC6A2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.